Evofem Biosciences, Inc. Overview
Pro stress-test →Evofem Biosciences is a San Diego-based pharmaceutical company commercializing two FDA-approved sexual and reproductive health products: PHEXX (lactic acid, citric acid, and potassium bitartrate) – the first and only hormone-free, on-demand prescription contraceptive vaginal gel, and SOLOSEC (secnidazole) 2g oral granules – an FDA-approved oral antibiotic for the treatment of two sexual health diseases: bacterial vaginosis (BV) and trichomoniasis. The company is pursuing international expansion through partnerships in new markets.
Strategic Profile
Pro stress-test →Evofem is executing a strategy to increase revenues and diversify its revenue stream through commercializing FDA-approved sexual health products outside the U.S. through strategic alliances such as the ones forged for MENA and Sub-Saharan Africa. However, the company faces significant financial headwinds with minimal U.S. domestic sales and heavy leverage.
Competitive Landscape
Pro stress-test →Evofem competes in women's sexual and reproductive health with limited domestic market presence. Competitors in contraceptive and STI treatment spaces include traditional pharmaceutical players with broader product portfolios and established distribution networks. The company's unique hormone-free on-demand contraceptive positioning differentiates PHEXX, but limited commercialization success and minimal U.S. revenue suggest market adoption challenges.
Industry Context
Evofem Biosciences, Inc. operates in Women's sexual and reproductive health pharmaceuticals.
Key facts
Founded: 2007 · Headquarters: San Diego, US · Employees: unknown · Revenue: $3.6M (annualized Q1 2026 rate) · Market cap: N/A